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We used SEREX technology to identify novel tumour-associated antigens in patients with primary hepatocellular carcinoma and
found serological responses to the polycomb group (PcG) protein BMI-1, which is overexpressed in a range of different tumour
types. Further studies identified T-cell responses to both BMI-1 and another PcG protein, EZH2, in cancer patients and at relatively
lower levels in some normal donors. We next identified several CD8þ T-cell epitopes derived from BMI-1 and EZH2 and
demonstrated that EZH2-derived peptides elicited more significant interferon-g (IFN-g) release than BMI-1-derived peptides. That
CD8þ T cells were responsible for the observed responses was confirmed for EZH2 by both IFN-g capture assays and tetramer
staining using an HLA-A0201-restricted, EZH2-derived YMSCSFLFNL (aa 666–674) epitope. The ability of YMSCSFLFNL (aa 666–
674) to stimulate the in vitro expansion of specific T cells from peripheral blood lymphocytes was greatly enhanced when the CD25
þ
T-cell population was depleted. EZH2-specific cytotoxic T lymphocyte clones specific for two HLA-A0201 epitopes were generated
and found to recognise endogenously processed EZH2 in both HLA-matched fibroblasts and tumour cell lines. Given the widespread
overexpression of PcG proteins in cancer and their critical role in oncogenesis, these data suggest that they may be useful targets for
cancer immunotherapy.
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Immunotherapeutic approaches to the treatment or prevention
of cancer have flourished in recent years (Rosenberg, 2001;
Rosenberg et al, 2004). This is largely due to the rapid
identification of tumour-associated antigens (TAAs), which has
been achieved by examining the specificity of existing T-cell
responses (Stevanovic, 2002), or by using screening strategies such
as serological identification of antigens by recombinant expression
cloning (SEREX) (Pfreundschuh, 2000), proteomic analysis, gene
expression profiling or combinations (Schultze and Vonderheide,
2001). The first tumour-specific vaccination was carried out in
malignant melanoma which remains a valuable model for
investigating cancer immunotherapy in humans (Saleh et al,
2005). With the growing number of TAAs identified, clinical
studies have been expanded to other carcinomas (Stevanovic,
2002) and most of these studies used MHC class I-restricted, T-cell
epitope peptides derived from TAAs to expand cytotoxic T cells
(CTLs) for tumour destruction. Although this approach has
the potential to induce antitumour immune responses, few studies
have shown significant clinical responses (Rosenberg et al,
2004). Possible reasons for this are that the peptides chosen
may not be naturally processed and presented by tumour cells,
immune escape and unsolved questions about optimal clinical
application. Recent studies implicate CD4
þCD25
þ regulatory T
cells (TREG) within the tumour microenvironment in suppression
of CD4þ and CD8þ T-cell activation and proliferation (Shevach
et al, 2001). Increased numbers of both peripherally circulating
and tumour-associated TREG have been observed in tumour-
bearing individuals with non-small lung, ovarian, breast, ovarian
and hepatocellular carcinoma (HCC) (Woo et al, 2001, 2002;
Liyanage et al, 2002; Ormandy et al, 2005; Unitt et al, 2005), and
increased numbers of infiltrating tumour TREG has been linked to a
striking reduction in patient survival in ovarian cancer (Curiel
et al, 2004).
With the exception of melanoma, the number of characterised
TAAs for most tumours is limited and there is an urgent need
to identify more TAAs and T-cell epitopes derived from their
sequences. To be effective vaccines, T-cell epitopes must be
naturally processed and presented antigenic targets capable of
eliciting T-cell responses. The ultimate goal is to provide multiple
tumour-associated epitopes presented by both MHC class I and
class II molecules.
Here, we describe the identification by SEREX screening
of a new TAA, the polycomb group (PcG) protein BMI-1, in
HCC. BMI-1 and a related protein EZH2 are constituents of two
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sdistinct classes of PcG proteins. They are important transcriptional
repressors that regulate gene activity by the formation of multi-
protein complexes, called PcG bodies, and the organisation of
chromatin into an inaccessible structure that cannot bind
transcription factors (Shao et al, 1999). Interestingly, EZH2
appears to be one of the PcG proteins essential for BMI-1
recruitment to the PcG bodies (Hernandez-Munoz et al, 2005). PcG
gene expression is tightly regulated and differs between different
tissues and cell types. The proteins ensure correct embryonic
development and are also major contributors to the regulation of
haematopoiesis in the adult organism (Jacobs and van Lohuizen,
2002). BMI-1 has been shown to be indispensable for the self-
renewal of neural (Molofsky et al, 2003) and haematopoietic stem
cells (Raaphorst, 2003), and it also has a key role in regulating the
proliferative activity of normal stem and progenitor cells (Lessard
and Sauvageau, 2003). EZH2 is essential for cellular proliferation
(Bracken et al, 2003). There is a clear connection between altered
PcG gene expression and oncogenesis. Several mammalian PcG
members have been implicated in the control of cellular
proliferation and tumorigenesis (Jacobs and van Lohuizen,
2002), and altered expression of PcG genes is linked to
transformation in cell lines and the induction of tumours in
mutant mice (Satijn et al, 1997; Satijn and Otte, 1999). Several
recent studies suggest that they also contribute to the development
of cancer in humans. Aberrant PcG protein expression, such as
overexpression, failure of downregulation or coexpression, has
been reported in Hodgkin’s lymphoma (Dukers et al, 2004), B-cell
lymphoma (Raaphorst et al, 2004), mantle cell lymphoma (Bea
et al, 2001; Visser et al, 2001), prostate cancer (Sellers and Loda,
2002; Varambally et al, 2002), breast carcinoma (Kleer et al, 2003;
Raaphorst et al, 2003; Kim et al, 2004), HCC (Shi et al, 2005) and
during lung carcinogenesis (Vonlanthen et al, 2001; Breuer et al,
2004). Some of these altered patterns of expression may be of
diagnostic and prognostic relevance (Varambally et al, 2002;
Raaphorst et al, 2003; Breuer et al, 2004; Kim et al, 2004). Our
study shows that BMI-1 and EZH2 are overexpressed in several
epithelial tumours and that both proteins are associated with
both humoral and T-cell responses, suggesting that they represent
a novel family of TAAs that might be potential targets for
immunotherapy.
MATERIALS AND METHODS
Patients and subjects
Serum and/or peripheral blood mononuclear cells (PBMCs) were
separated from heparinised blood samples (25–30ml) taken from
patients with a variety of epithelial tumours and from healthy
donors. Histocompatibility locus antigen (HLA) class I tissue
typing was carried out at the National Blood Service, Birmingham,
UK. Tumour tissue was obtained from patients undergoing
diagnostic biopsy or surgical resection. Normal tissue was taken
from areas of tissue showing no tumour involvement. Approval
was obtained from the South Birmingham Research Ethics
Committee. Informed consent was obtained from all subjects.
Synthetic peptides
CD8þ T-cell epitopes derived from both the BMI-1 and EZH2
proteins predicted to bind to HLA-A0201, HLA-B2702/05 and
HLA-B440/3 were identified using the BioInformatics and
Molecular Analysis Section website (Parker et al, 1994) (Table 1)
and synthesised using fluoronylmethoxycarbonyl chemistry (Alta
Bioscience, Birmingham, UK).
Generation of BMI-1 and EZH2 constructs and
recombinant adenoviruses
BMI-1 or EZH2 DNA sequences (a kind gift from Professor
Thomas Jenuwein) were ligated into the pAdTrack-CMV vector
containing the sequence for green fluorescent protein (GFP) and
used directly in the nucleofection experiments. The empty vector
encoding GFP was used as the negative control. Recombinant
adenoviruses were produced by recombining the EZH2-containing
pAdTrack-CMV vectors or the empty pAdTrack-CMV with the
pAdEasy-1 vector and purified on caesium chloride gradients.
SEREX screening of human sera against a HCC cDNA
library
All serum samples were preabsorbed before SEREX screening. The
primary screen was carried out using a commercially available
HCC cDNA library (Novagen, Darmstadt, Germany). Serum from
patients with HCC was tested initially and any positive clones
screened against a panel of human serum from non-cancer donors.
Samples were tested at a dilution of 1:1000 and positive plaques
detected by alkaline phosphatase-conjugated goat anti-human IgG
antibody (Sigma, Gillingham, Dorset, UK; 1:1000) and staining
with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetra-
zolium (BioRad, Richmond, USA). Positive plaques were re-
screened to eliminate those encoding human immunoglobulin
sequences. Phage DNA from positive clones was converted to
stable plasmid subclones in BM25.8 cells and then transformed
into JM109 cells before sequencing.
Immunohistochemical staining for BMI-1
A variety of tumours, tumour cell lines and normal tissue were
stained for the expression of BMI-1. Antigen retrieval was
performed using the ALTER technique (Reynolds et al, 2002)
and staining with the monoclonal antibodies to BMI-1 (229F6;
Upstate, Watford, UK; 1:100) and 6C9 (1:10) was detected using
Vector NovaRed (Vector Laboratories, Peterborough, UK) or DAB
(Dako, Ely, Cambs, UK). The extent of staining was assessed
Table 1 Peptide sequences from BMI-1 and EZH2 predicted to bind HLA class I molecules
HLA class I restriction element BMI-1
a Amino-acid position EZH2
b Amino-acid position
A0201 TLQDIVYKL 74–82 YMCSFLFNL 666–674
CLPSPSTPV 271–279 SQADALKYV 734–742
B2702/05 VRYLETSKY 44–52 KRFRRADEV 30–38
KRYLRCPAA 161–169 YRYSQADAL 731–739
B4403 YEEEPLKDY 195–203 EELFVDYRY 725–733
KEEVNDKRY 155–163 KESRPPRKF 210–218
Peptides were predicted using the BioInformatics and Molecular Analysis Section (BIMAS) website (Parker et al, 1994).
aBMI-1 accession number NM_005180.
bEZH2 accession
number NM_004456.
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positively staining nuclei as follows: negative (o1% of cells
positive), 1 (l–5%), 2 (5–10%), 3 (10–25%), 4 (25–50%) and 5
(450%).
Reverse transcription–PCR to detect EZH2 mRNA
RNA was isolated using the PolyATract system 1000 kit (Promega,
Southampton, UK). First-strand cDNA was synthesised using
SuperScript II reverse transcriptase with Oligo-dT priming (Invitro-
gen, Paisley, UK). Reverse transcription–PCR was performed for
EZH2 using forward and reverse primers 50-CGGGGCTCCAAAAAG
CATCTAT-30 and 30-GTCTGGATGGCTCTCTTGGCAA-50, respec-
tively, with a hot start of 941C for 3min followed by 30 cycles of
941C, 30s; 591C, 30s and 721C, 45s.
Preparation of PBMCs and tumour-infiltrating
lymphocytes
Peripheral blood mononuclear cells were separated from hepar-
inised blood using Lymphoprep (Nycomed, Roskilde, Denmark)
and cryopreserved. After thawing, cells were recovered overnight
in RPMI 1640 medium containing 10% FCS (RPMI/10% FCS).
CD4þ and CD8þ T-cell depletions were carried out using
antibody-coated magnetic beads (Dynal, Paisley, UK) according to
the manufacturer’s instructions and depletion confirmed by flow
cytometry. Tumour-infiltrating lymphocytes (TILs) were extracted
from liver tumour tissue by homogenisation in RPMI/10% FCS
followed by density gradient centrifugation through Lymphoprep.
ELISPOT assay of interferon-c release
Interferon-g (IFN-g) release was measured using a commercially
available enzyme-linked immunospot (ELISPOT) kit (ELISPOT
assay for human interferon-g; Mabtech, Sweden) using cytokine
capture and detection reagents according to the manufacturer’s
instructions. Peripheral blood mononuclear cells, CD4-depleted or
CD8-depleted responder cells were seeded in triplicate wells and
peptides added at 10mgml
 1. Negative control wells contained
irrelevant peptide or diluted DMSO and positive control wells
contained 10mgml
 1 PHA (Sigma) or an HLA-matched peptide
epitope derived from Epstein–Barr virus (EBV). Spots were
counted using an automated system.
Interferon-c release following nucleofection of PBMCs
Recovered PBMCs (2–10 10
6) were nucleofected according to
the manufacturer’s instructions (Amaxa Biosystems, Cologne,
Germany) with 5mg of plasmid DNA (pAdTrack-CMV vectors)
encoding BMI-1 and GFP, EZH2 and GFP, or GFP alone as a
negative control. Transfection efficiency was assessed after 24h by
fluorescent microscopy, and nucleofected cells were serially diluted
into triplicate wells in 96-well U-bottomed plates (Nunc-Invitro-
gen, Paisley, UK) and left overnight at 371C. Interferon-g secretion
in each well was determined by ELISA using 50ml of supernatant,
capture and biotinylated detection monoclonal antibodies against
IFN-g (Endogen; 2G1 at 0.75mgml
 1 and B133.5 at 0.375mgml
 1,
respectively), and then ExtrAvidin-Peroxidase (Sigma; 1:1000)
followed by the addition of 3,30,5,50-tetramethylbenzidine substrate
solution (Sigma). Interferon-g standard solutions (31.25–
2000pgml
 1) were also run in triplicate.
Detection and enrichment of EZH2-specific CD8þ T cells
based on IFN-c secretion
Detection and enrichment of EZH2-specific T cells was carried
out using the Miltenyi Cytokine Secretion Assay PE kit for IFN-g
(Miltenyi Biotec, Surrey, UK) according to the manufacturer’s
instructions. Peripheral blood mononuclear cells isolated from
HLA-A0201 donors were stimulated overnight at 371C with the
HLA-A0201-restricted, EZH2 peptide YMCSFLFNL (aa 666–674)
at 10mgml
 1. Negative control cultures contained diluted DMSO
and positive controls staphylococcal enterotoxin B (Sigma) at
1mgml
 1. Interferon-g-secreting cells were selected on automated
columns. Pre- and postselected samples were analysed by flow
cytometry using anti-human CD8-PC5 (Beckman Coulter,
High Wycombe, Bucks, UK) with propidium iodide to gate out
dead cells.
Detection of EZH2-specific T cells using fluorogenic
tetramers
Tetramers incorporating the HLA-A0201-restricted EZH2 epitope
YMCSFLFNL (aa 666–674) (Table 1) were produced as previously
described (Altman et al, 1996). Peripheral blood mononuclear cells
from HLA-A0201 donors were incubated with the tetramer and
the FITC-conjugated CD8 antibody (T8; Beckman Coulter) for
20min at 371C and analysed by flow cytometry. Tetramer staining
was performed on Peripheral blood mononuclear cells either
directly ex vivo, or following 14 days in culture with the
YMCSFLFNL (aa 666–674) peptide and cytokines human rIL-2
(Chiron, Oxford, UK; 10Uml
 1) and rIL-7 (Peprotech, London,
UK; 20ngml
 1) replenished every 3 days. In some experiments,
CD25þ cells were depleted using the Magnetic Cell Sorting System
(Miltenyi Biotech) before peptide stimulation in vitro. Depletions
were verified by flow cytometry using anti-human CD25-PC5
(Beckman Coulter) and anti-human CD4-PE (Pharmingen, Cowley,
Oxford, UK).
Isolation of EZH2-specific cytotoxic T-cell clones
Peripheral blood mononuclear cells were stimulated with peptide
(1–100mM) for 1–2h at 371C, washed, and resuspended in T-cell
medium (RPMI 1640 containing 10% FCS, 2mM glutamine and
penicillin/streptomycin), supplemented with 25ngml
 1 rIL-7
(Peprotech) and 10Uml
 1 rIL-2 after 3 days. Cultures were
restimulated after 1 week using irradiated peptide-loaded auto-
logous PBMCs (4000Rads), and cloned by limiting dilution to 0.3,
3 and 30 cellswell
 1 on day 14. Each well also contained 1 10
4
irradiated peptide-loaded autologous lymphoblastoid cells (LCL)
generated by in vitro transformation of B cells using the EBV
isolate B95.8 (Miller and Lipman, 1973), and 1 10
5 irradiated
PHA-stimulated mixed allogeneic buffy coat feeder cells (NBS,
Birmingham). Cloning medium comprised T-cell medium contain-
ing 1% human AB serum (Gibco-Invitrogen, Paisley, UK),
100Uml
 1 rIL-2 and 30% supernatant from the MLA 144 cell
line. Positive clones (initially screened against peptide-loaded
autologous LCL target cells in an ELISA of IFN-g release) were
transferred to separate 2ml wells in 1ml of T-cell medium with
1 10
5 irradiated peptide-loaded autologous LCL and 1 10
6
irradiated PHA-stimulated mixed allogeneic buffy coat feeder cells.
Wells were maintained by feeding twice weekly and were
restimulated once a month.
Cytotoxicity was measured using chromium release assays as
previously described (Lee et al, 1997). Target cells labelled with
[
51Cr]O4 were used at 2.5 10
3 cellswell
 1 with T cells added at
known effector:target ratios. Histocompatibility locus antigen-
A0201-positive primary human fibroblasts (infected with recom-
binant adenoviruses RAdEZH2 and RAdControl at a multiplicity
of infection of 30 for 48h before labelling) and tumour cell lines
(LNCaP, HepG2 and MCF7) were employed as target cells in these
assays. In some experiments, targets were cultured with IFN-g
(1000Uml
 1) for 48h before assay and/or incubated with the anti-
human HLA-A0201 monoclonal antibody BB7.2 (1mgwell
 1) for
1h at 371C after labelling and before the addition of T cells.
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Identification of the PcG protein BMI-1 as a TAA in HCC
using SEREX technology
Screening of an HCC cDNA library with serum from patients
with HCC (not associated with viral hepatitis) using SEREX
technology revealed an antigen which when sequenced was
shown to be a member of the PcG family called BMI-1. Serum
from nine HCC patients studied reacted strongly with BMI-1
(Table 2; Supplementary Material), suggesting that immune
responses to this antigen are frequent in HCC. The SEREX
screening identified three sequences representing different cDNA
clones of BMI-1, and all nine HCC serum samples screened
had antibody responses to at least one of these. The majority
of the noncancer serum samples also showed reactivity to BMI-1,
but this was generally weaker as determined by intensity of plaque
staining.
Expression of BMI-1 and EZH2 in normal and tumour
tissue
Before embarking on a more detailed study of cellular immune
responses to BMI-1, its expression was examined in a panel of
tumour tissue samples and cell lines. All samples, both tissue
sections and cell lines, displayed upregulation of the BMI-1 protein
(Table 3; Supplementary Material). There was strong, specific,
nuclear staining for BMI-1 involving at least 50% of cells in all
of the cases studied and in some instances nearly 100% of the
tumour cell population were positive (Figure 1A). There was
minimal immunohistochemical staining for BMI-1 (o1% of cells)
in normal tissues from breast, stomach, colon or skin (Table 2;
Supplementary Material). Three of the four normal liver samples
showed slightly more extensive nuclear staining involving o10%
of hepatocytes. Occasional infiltrating lymphocytes were also
positive in normal tissue specimens. There is currently no
commercially available antibody for EZH2, so we used RT–PCR
to analyse EZH2 mRNA expression in tumour cell lines. High-level
expression of EZH2 mRNA was observed in the prostate cancer cell
line LNCaP, the HepG2 hepatoblastoma cell line and three breast
cancer cell lines MCF7, BT549 and nDA-MB436. This confirms
previous studies demonstrating upregulation of EZH2 expression
in tumours of patients with breast cancer (Kleer et al, 2003;
Raaphorst et al, 2003; Kim et al, 2004). Variable expression was
seen in a number of EBV-transformed LCL, with low expression of
EZH2 mRNA in the cervical carcinoma cell line Caski, and in
normal fibroblasts (Figure 1B).
Systemic T-cell responses to BMI-1 and EZH2 can be
detected in patients with solid tumours
We tested for immune responses to BMI-1 and EZH2 by measuring
IFN-g production from PBMC cultures nucleofected with plasmid
DNA (pAdTrack-CMV) encoding the EZH2 and BMI-1 proteins.
Background levels of IFN-g production following nucleofection
were assessed using the empty pAdTrack-CMV vector, which
encodes GFP alone, and were generally low. The presence of GFP
in the pAdTrack-CMV vectors expressing BMI-1 and EZH2 also
allowed an assessment of the nucleofection efficiency, which was
generally between 1 and 2%.
Responses to BMI-1 were seen in one out of 10 HCC patients,
two out of six prostate cancer patients and three out of five
colorectal cancer patients. EZH2 reactivity was observed in three
out of ten HCC patients, one out of five colorectal cancer patients
and in none of the prostate cancer samples. One sample from both
the HCC group and the colorectal cancer group demonstrated
T-cell reactivity to both antigens. No responses were seen to either
antigen in the three breast cancer patients investigated. Although
the numbers investigated in each group were small, there appeared
to be a dominant response to BMI-1 in the patients with colorectal
and prostate cancer, whereas stronger reactivity to EZH2 was more
common among the HCC patients. Typical responses from each
group are shown in Figure 2A where it can be seen that levels of
IFN-g production were reasonably high. Figure 2B shows the
results of a paired PBMCs and TILs population from a patient
with HCC. No T-cell reactivity was seen in the nucleofected PBMC
cultures to either BMI-1 or EZH2, but interestingly IFN-g
production was extremely high in the TILs culture expressing
BMI-1, suggesting that immune responses may be compartmenta-
lized in the tumour. These data demonstrate that T-cell responses
to both BMI-1 and EZH2 are evident in cancer patients.
To confirm the T-cell responses in patients with HCC, we used
CD8þ T-cell peptide epitopes derived from both the BMI-1 and
EZH2 proteins predicted to bind to HLA-A0201, HLA-B2702/05
and HLA-B4402/03 molecules (Table 1) in ELISPOT assays of
IFN-g release. Eleven patients of the appropriate HLA type were
investigated and typical results are shown in Figure 3A and B.
Prostate cancer
Breast cancer
Hepatocellular 
carcinoma
HepG2 cell line 
Colorectal cancer
LNCaP cell line
A
B
EZH2
GAPDH
Figure 1 Expression of BMI-1 and EZH2.( A) Immunohistochemical
staining for BMI-1 expression on biopsy sections taken from different
carcinomas and tumour cell line cytospins using the 229F6 monoclonal
antibody. (B) Reverse transcription–PCR using EZH2-specific primers of
various cell lines: 1, prostate cancer cell line (LNCaP); 2, normal human
fibroblasts; 3, lymphoblastoid cell line(LCL)1; 4, LCL2; 5, LCL3; 6, LCL4; 7,
cervical cancer cell line (Caski); 8, hepatoblastoma cell line (HepG2); 9,
breast cancer cell line (MCF7); 10, breast cancer cell line (BT549); 11,
breast cancer cell line (nDA-MB 436); 12, water.
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Figure 2 Interferon-g production by PBMC and TIL cultures from cancer patients and normal donors following nucleofection with plasmid DNA
expressing BMI-1 and EZH2 proteins. Peripheral blood mononuclear cells samples from patients with a variety of (A) epithelial tumours and (C) normal
donors were nucleofected with 5mg of plasmid DNA (pAdTrack-CMV) encoding either BMI-1 and GFP ( ), or EZH2 and GFP (’) or GFP alone (&). (B)
Results from paired cultures of TILs and PBMCs from a patient with hepatocellular carcinoma are also shown. Interferon-g production was measured in the
supernatants of serially diluted PBMC cultures using an ELISA. The results shown are means of triplicate wells and standard errors were always less than 10%.
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Figure 3 ELISPOT responses in patients with hepatocellular carcinoma (HCC) and normal donors to predicted CD8þ T-cell epitope peptides.
Unfractionated PBMCs or CD4- and CD8-depleted responder cell populations were screened against 9-mer peptides derived from BMI-1 and EZH2
proteins predicted to bind to the HLA class I molecules HLA-A0201, HLA-B2702/05 and HLA-B4403 (Table 1) using an ELISPOT of interferon-g release.
The figure shows positive responses to the HLA-A0201-restricted BMI-1 peptides TLQDIVYKL (aa 74–82; TLQ) and CLPSPSTPV (aa 271–279; CLP) in
HCC patient 001 (A), to the HLA-B2702/05-restricted BMI-1 peptides VRYLETSKY (aa 44–52; VRY) and KRYLRCPAA (aa 161–169; KRY) in normal
donor 001 (C), and to the HLA-A0201-binding EZH2 peptides YMCSFLFNL (aa 666–674; YMC) and SQADALKYV (aa 734–742; SQA) in HCC patient
002 (B) and normal donor 001 (D). Peptides were added to a final concentration of 10mgml
 1 and results obtained from background control wells
containing cells and diluted DMSO are shown. Results are the mean of triplicate wells, and are expressed as the number of spots obtained per 1 10
6 cells
added to each well. Standard errors were less than 10%. For depleted populations, these figures were calculated following FACS analysis after depletion.
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peptides, were detected in three individuals with one showing
reactivity to the CLPSPSTPV (aa 271–279), one to TLQDIVYKL (aa
74–82) and one to both peptides (Patient 001 shown in Figure 3A).
Two out of the 11 gave a positive response to the HLA-A201-
binding epitopes YMCSFLFNL (aa 666–674) and SQADALKYV (aa
734–742) derived from EZH2. To confirm that these were CD8þ
T-cell responses, we compared unfractionated PBMCs with CD4- or
CD8-depleted responder cell populations (FACS analysis confirmed
depletion of greater than 99% of the appropriate T-cell subset)
(Patient 002 shown in Figure 3B). The magnitude of the responses
to the EZH2 peptides was generally greater than those to BMI-1.
Weaker T-cell responses to BMI-1 and EZH2 are also seen
in normal donors
We also investigated T-cell reactivity to BMI-1 and EZH2 in normal
laboratory donors by measuring IFN-g production from PBMC
cultures expressing BMI-1 and EZH2 proteins following nucleofec-
tion (as above). Background levels of IFN-g production to the
control GFP-expressing plasmid were again low and nucleofection
efficiency was consistently 1–2%. Two out of the eight normal
samples investigated demonstrated reactivity to BMI-1, and four to
EZH2. Interferon-g production was generally 10–20 times lower
than with samples from patients with cancer (Figure 2C).
In the ELISPOT assay, two out of 10 normal donors showed a
response to BMI-1-predicted peptides. One individual demon-
strated reactivity to the HLA-A201-binding peptide TLQDIVYKL
(aa 74–82), and the other to the HLA-B2702/05-binding peptides
VRYLETSKY (aa 44–52) and KRYLRCPAA (aa 161–169; Donor
001 shown in Figure 3C). EZH2 reactivity was observed in two out
of seven donors. Both showed a positive response to the HLA-
A201-binding epitopes YMCSFLFNL (aa 666–674) and SQADALK-
YV (aa 734–742), which depletion experiments confirmed to be
CD8þ T-cell reactivity (Donor 001 shown in Figure 3D), and one
of these individuals also showed weaker reactivity against two
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Figure 4 Detection and enrichment of IFN-g secreting cells from normal donors. Peripheral blood mononuclear cells obtained from normal HLA-A0201-
positive laboratory donors were stimulated in vitro overnight with the HLA-A0201-restricted EZH2 peptide YMCSFLFNL (aa 666–674) at 10mgml
 1.
Interferon-g-secreting cells were detected using a PE-labelled IFN-g detection antibody, enriched on anti-PE magnetic microbeads and selected on
automated columns. The figure shows flow cytometric analysis of pre- and postselected samples (stained using an anti-human CD8-PC5 antibody) from the
same donor. Dead cells have been gated out after staining with propidium iodide.
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sputative HLA-B4403-restricted peptides EELFVDYRY (aa 725–
733) and KESRPPRKF (aa 210–218). The magnitude of the
responses obtained from normal donors for both BMI-1 and
EZH2 was less than that for HCC patients.
A cytokine secretion assay based on IFN-g was employed for the
detection and enrichment of peripheral blood T cells from normal
donors that responded to the EZH2-predicted epitope
YMCSFLFNL (aa 666–674). Eight HLA-A0201-positive laboratory
donors were tested and significant enrichment of EZH2-specific
CD8
þ T cells was seen in five of these (Figure 4). We then used
MHC class I tetramers incorporating the HLA-A0201-restricted
EZH2 epitope YMCSFLFNL (aa 666–674) to further demonstrate
systemic T-cell reactivity to EZH2. Peripheral blood mononuclear
cells isolated from seven HLA-A0201-positive healthy laboratory
donors were stained directly ex vivo with the tetramer, and
between 0.05 and 0.75% (median 0.15%) CD8þ T cells stained. In
four out of six of the normal PBMC samples, the percentage of
tetramer-positive CD8þ T cells could be increased by carrying out
a 14-day in vitro incubation with the YMCSFLFNL (aa 666–674)
peptide (range 0.03–1.04%; median 0.585%) (Figure 5A and B).
Depletion of CD25þ T cells allows greater in vitro
expansion of EZH2-specific T cells
We hypothesized that EZH2-specific T cells might be suppressed in
vivo by regulatory T cells. In order to test this, CD25þ T-cell
depletion was carried out on six HLA-A0201-positive normal
PBMC samples (99% of CD4þCD25þ T cells were depleted)
and subsequent in vitro restimulation with the YMCSFLFNL (aa
666–674) peptide carried out for 14 days. In two out of six of
the samples, a marked expansion of YMCSFLFNL (aa 666–674)-
tetramer positive cells was detected. The data for one of these are
shown in Figure 5, where it can be seen that 0.67% of cells within
the CD8þ T-cell fraction were tetramer positive without CD25
depletion as opposed to 2.04% with CD25 depletion.
EZH2-specific T-cell clones are cytotoxic against
endogenously processed antigen and tumour cell lines
EZH2-specific CTL clones specific for the HLA-A0201-restricted
peptide epitopes YMCSFLFNL (aa 666–674) and SQADALKYV (aa
734–742) were isolated from both HLA-A0201-positive HCC
patients and normal donors by peptide restimulation in vitro.
Antigen-specific cytotoxicity was observed against HLA-A0201-
matched fibroblasts infected with a recombinant adenovirus
encoding EZH2 (RAdEZH2) (Figure 6A) and the breast carcinoma
cell line MCF7, which naturally expresses EZH2 (Figure 6B).
Greater levels of lysis were observed following incubation of the
tumour cells with IFN-g and T-cell reactivity was either greatly
reduced or effectively blocked following incubation of the target
cells with the anti-HLA-A0201 monoclonal antibody BB7.2. Low
levels of killing were observed against the HLA-A0201-positive
LNCaP prostate cancer cell line and HepG2 hepatoblastoma cells
(data not shown).
DISCUSSION
We employed SEREX technology using a cDNA library to identify
new TAAs associated with liver cancer. The SEREX approach
was chosen because the method identifies antigens that are of
immunological relevance, as their detection requires patients to
have generated antibodies against them. SEREX has previously
detected tumour antigens with epitopes for cellular immune
responses, the best-known example being NY-ESO-1 (Gnjatic et al,
2002). In our study, screening of an HCC cDNA library with serum
from patients with nonvirally induced HCC revealed different
antigens, with a particularly strong response from all patient
samples to the PcG protein BMI-1 (Table 2; Supplementary
Material). This strong reactivity, together with the fact that the PcG
proteins are known to be vitally involved in transcriptional control
and carcinogenesis in humans, and may therefore be less
susceptible to the development of ‘immune escape’ variants, made
BMI-1 an attractive candidate for validation as a target for cancer
immunotherapy. Recent studies showing that another polycomb
protein, EZH2, which is essential for BMI-1 recruitment to the
polycomb body in the nucleus (Hernandez-Munoz et al, 2005), is
also highly expressed in many cancers and led us to extend our
studies to include both BMI-1 and EZH2. As expression of these
two proteins is often mutually exclusive, a sensible approach may
be an attempt to target both.
Consistent with recent studies demonstrating overexpression of
PcG genes in cancer (Vonlanthen et al, 2001; Sellers and Loda,
2002; Kleer et al, 2003; Raaphorst et al, 2003; Breuer et al, 2004;
Kim et al, 2004; Shi et al, 2005), we found that both BMI-1 and
EZH2 are strongly expressed by a variety of tumours (Table 3;
Supplementary Material; Figure 1). This broad upregulation in
cancer makes them attractive immunotherapeutic targets for
malignant disease. Low level expression of both proteins was also
observed in some normal tissues, which is consistent with the
reported role of BMI-1 and EZH2 in self-renewal and proliferative
activity of stem cells and their progenitors (Bracken et al, 2003;
Molofsky et al, 2003). The low-level restricted expression on
normal tissues suggests that effective immune responses against
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Figure 5 Staining of normal PBMCs with theYMCSFLFNL (aa 666–674) tetramer. Peripheral blood mononuclear cells isolated from an HLA-A0201-
positive normal laboratory donor were stained with a tetramer incorporating the HLA-A0201-restricted EZH2 epitope YMCSFLFNL (aa 666–674) and an
FITC-conjugated surface CD8 antibody directly ex vivo (A) and following a 14-day in vitro restimulation step with the YMCSFLFNL (aa 666–674) peptide
(B). Peptide restimulation was also carried out on the same population of PBMCs after depletion of CD25
þ T cells (C). The values shown are the
percentage of CD8þ T cells staining positive with the tetramer.
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sBMI-1 and EZH2 may be compromised by self-tolerance and that
stimulating immune reactivity to these proteins may be accom-
panied by autoimmune side effects. However, the majority of
cancer-specific immunotherapies have employed self-antigens and
autoimmunity has not proven to be a significant problem in most
clinical studies (Gilboa, 2004).
Because CTL responses are important for tumour destruction,
the demonstration of CTL responses against PcG proteins would
strengthen their potential as tumour antigens. Initially, we looked
for IFN-g secretion from PBMCs that had been nucleofected with
plasmids encoding either the BMI-1 or EZH2 proteins. A system
optimised for the transfection of dendritic cells was employed so
that monocytes and macrophages would be preferentially nucleo-
fected. Fluorescence-activated cell sorter (FACS) analysis revealed
that T cells and B cells were also expressing the proteins and that
transfection efficiencies were around 1–2%. Earlier experiments
using EBV antigens had established that these conditions provided
effective antigen processing and presentation and reliable antigen-
specific IFN-g responses using low numbers of cells (Figure 7).
Patients with HCC, prostate cancer, colorectal cancer and breast
cancer were studied, and with the exception of breast cancer, T-cell
reactivity to BMI-1 and/or EZH2 was observed in all groups.
Predicted CD8þ T-cell epitopes derived from BMI-1 and EZH2
also elicited T-cell responses as assessed by IFN-g release
confirming the presence of CD8 responses against these proteins
in patients with cancer. These data also confirmed that these
epitopes identified by predictive algorithms are likely to represent
naturally presented epitopes and may therefore be significant for
the design of peptide-based vaccines.
The SEREX screening demonstrated reactivity to cDNA clones
representing BMI-1 in serum obtained from most of the noncancer
patients, and T-cell assays also detected BMI-1- and EZH2-specific
T-cell responses in normal individuals using either nucleofection
of PBMCs or ELISPOT assays with T-cell epitopes. Enrichment of
IFN-g secreting CD8þ T cells specific for YMCSFLFNL (aa 666–
674) was possible in five out of eight normal donors (Figure 4B)
and systemic T-cell responses to EZH2 were demonstrated in
HLA-A0201-positive normal donors by YMCSFLFNL (aa 666–
674)-tetramer staining. Significantly, with the majority of these
samples, the percentage of CD8þ T cells, which stained positive,
could be increased by carrying out an in vitro restimulation step
with the YMCSFLFNL (aa 666–674) peptide. The fact that these
EZH2-specific T cells could be expanded in vitro is encouraging
because it opens up the possibility of either adoptive T-cell therapy
or expansion in vivo by vaccination.
It is perhaps not surprising that responses to BMI-1 and EZH2
were detected in normal donors, as there are likely to be
autoreactive T cells of low avidity present in the mature T-cell
population for the majority of self-antigens. This has been
demonstrated for other TAAs (Marincola et al, 1996). In fact, it
is the vulnerability of the immune system to activate anti-self
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Figure 6 Cytotoxicity of EZH2-specific cytotoxic T-cell clones 691, 696 and 480 derived from normal donor 001 and HCC patient 002 against (A) HLA-
A0201-matched primary human fibroblasts infected with recombinant adenoviruses (either RAdEZH2 or RAdControl) and (B) the HLA-A0201-positive
breast carcinoma cell line MCF7. Chromium release assays employed 2.5 10
3 target cellswell
 1. Effector:target cell ratios and additions of either IFN-g or
monoclonal antibody BB7.2 are indicated on individual graphs. The results shown are means of triplicate wells and standard errors were less than 10%.
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Figure 7 Interferon-g production by a PBMC culture from a normal
donor following nucleofection with plasmid DNA expressing the E3C
protein from EBV protein. Peripheral blood mononuclear cells were
nucleofected with 5mg of plasmid DNA encoding E3C or the empty vector
and IFN-g production was measured after 48h incubation.
BMI-1 and EZH2 are tumour-associated antigens
JC Steele et al
1209
British Journal of Cancer (2006) 95(9), 1202–1211 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
simmunity that is the basis for developing useful cancer-specific
immunotherapies and it is of note that, although the frequency of
detected responses to PcG proteins was similar between normal
and cancer patients, the normal donors consistently showed a
weaker immune response. It is intriguing to speculate that immune
responses to PcG proteins could be involved in the control of
normal haematopoeisis and/or regulating stem cell renewal.
The study revealed differences in responses between BMI-1 and
EZH2 with both cancer patients and normal donors. Interferon-g
production following nucleofection was more readily detected in
response to BMI-1 in the patients with colorectal and prostate
cancer, whereas the HCC patients tended to have stronger
responses to EZH2. This dominant response to EZH2 in the HCC
group was also apparent with the ELISPOT assays, where the
magnitude of the responses to the EZH2 peptides was generally
greater than those to BMI-1. EZH2 T-cell reactivity was more
common than BMI-1 reactivity among normal donors also,
suggesting that BMI-1 may be less immunogenic than EZH2.
BMI-1 is more widely expressed on stem cell populations (Lessard
and Sauvageau, 2003; Raaphorst, 2003) and so represents an
important regulatory antigen associated with a more ‘primitive’
cell type. It could be that the immune system is, therefore, more
tolerant to BMI-1 than EZH2. The strong response to BMI-1 among
some of the patients with colorectal and prostate cancer may be
due to the pattern of aberrant expression of the polycomb proteins
by these tumours. Overexpression of BMI-1 may result in a break
in tolerance and reactivation of autoreactive T cells by exposure to
high concentrations of antigen.
EZH2-specific T-cell clones were obtained by in vitro peptide
restimulation using the HLA-A0201-restricted CD8þ T-cell
epitope YMCSFLFNL (aa 666–674). These clones were able to
recognize and kill target cells overexpressing EZH2 following
infection with a recombinant adenovirus, and also the HLA-A0201-
matched breast tumour cell line MCF7. Blocking experiments with
the BB7.2 monoclonal antibody against HLA-A0201 confirmed that
this recognition and cytotoxicity was MHC class I-restricted. It was
encouraging that T cells cloned in response to an EZH2-derived
peptide could recognize endogenously processed and presented
antigen, suggesting that EZH2-specific T cells would be able to
recognize and kill tumour cells. Functional EZH2-specific T cells
have previously been isolated from patients with prostate cancer
using HLA-A2402-restricted peptides. These effectors were shown
to be cytotoxic against the C1R-A24 subline of C1R lymphoma and
also the prostate cancer cell line LNCaP, which had been stably
transfected with the HLA-A2402 gene (Ogata et al, 2004).
It has been suggested that SEREX identifies self-antigens that
elicit naturally occurring CD4þCD25þ regulatory T cells (TREG)
which maintain and regulate immunological homeostasis
(Nishikawa et al, 2005) and our study supports this hypothesis. In
experiments using the EZH2-derived HLA-A0201-restricted peptide
YMCSFLFNL (aa 666–674), we were able to show that depletion of
CD25
þ T cells promotes the expansion of YMCSFLFNL (aa 666–
674)-tetramer positive cells in normal PBMC cultures undergoing
peptide restimulation in vitro. This suggests that TREG do play a role
in suppressing at least CD8þ T-cell reactivity to EZH2. In tumours,
where numbers of TREG may be greatly increased, this immuno-
suppressive effect may be highly significant.
We have demonstrated that the PcG proteins BMI-1 and EZH2
represent promising target antigens for cancer immunotherapy.
They are expressed on a wide variety of tumours where they
appear essential to the oncogenic process and show restricted
expression in normal tissue. They are naturally immunogenic and
EZH2-specific T cells can be reactivated and expanded in vitro by
a combination of antigen stimulation and TREG depletion. Most
importantly, these T cells can recognize endogenously processed
antigen and are cytotoxic against tumour cell lines naturally
expressing EZH2, suggesting that PcG proteins are a novel group of
TAA with potential as antigens for immunotherapy in a wide range
of cancers.
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